TY - JOUR
T1 - Tumor necrosis factor-α and mortality in heart failure
T2 - A community study
AU - Dunlay, Shannon M.
AU - Weston, Susan A.
AU - Redfield, Margaret M.
AU - Killian, Jill M.
AU - Roger, Véronique L.
PY - 2008/8/5
Y1 - 2008/8/5
N2 - Background - Tumor necrosis factor-α (TNFα), an inflammatory cytokine, was reported to be elevated in trials of heart failure (HF) with reduced ejection fraction (EF) and associated with mortality. Whether this is true for HF with preserved EF is unknown, and community data are lacking. We evaluated the distribution of TNFα, its association with baseline characteristics and mortality, and its benefit in assessing risk in community HF patients. Methods and resluts - Olmsted County residents with active HF from July 2004 to March 2007 (n=486; mean age, 76.7 years; EF ≥50%, 55%) were prospectively recruited. Clinical characteristics and TNFα were measured. Elevated TNFα (more than the assay limit of normal of 2.8 pg/mL) was present in 143 (29%). Higher TNFα was associated with decreased creatinine clearance, nonsmoking status, anemia, and greater comorbidity (P trend<0.05 for all). Mortality increased with increasing TNFα (P=0.016), with 1-year mortality estimates of 16%, 18%, 23%, and 32% from the lowest to highest quartile, respectively. After adjustment for age, sex, and EF, the hazard ratios for death were 1.24, 1.37, and 1.90 from the second to the highest TNFα quartile, respectively (P trend=0. 007). TNFα contributed to risk assessment as indicated by increases in the area under the receiver operating characteristic curves in all models examined (P<0.05 for all). Results did not differ by EF (P=0.60 interaction term of TNFα and EF). Conclusions - TNFα was elevated in a large portion of community HF patients, was associated with a large decrease in survival, and provided a significant incremental increase in risk assessment above established indicators. TNFα is useful for risk assessment in HF patients with preserved and reduced EF.
AB - Background - Tumor necrosis factor-α (TNFα), an inflammatory cytokine, was reported to be elevated in trials of heart failure (HF) with reduced ejection fraction (EF) and associated with mortality. Whether this is true for HF with preserved EF is unknown, and community data are lacking. We evaluated the distribution of TNFα, its association with baseline characteristics and mortality, and its benefit in assessing risk in community HF patients. Methods and resluts - Olmsted County residents with active HF from July 2004 to March 2007 (n=486; mean age, 76.7 years; EF ≥50%, 55%) were prospectively recruited. Clinical characteristics and TNFα were measured. Elevated TNFα (more than the assay limit of normal of 2.8 pg/mL) was present in 143 (29%). Higher TNFα was associated with decreased creatinine clearance, nonsmoking status, anemia, and greater comorbidity (P trend<0.05 for all). Mortality increased with increasing TNFα (P=0.016), with 1-year mortality estimates of 16%, 18%, 23%, and 32% from the lowest to highest quartile, respectively. After adjustment for age, sex, and EF, the hazard ratios for death were 1.24, 1.37, and 1.90 from the second to the highest TNFα quartile, respectively (P trend=0. 007). TNFα contributed to risk assessment as indicated by increases in the area under the receiver operating characteristic curves in all models examined (P<0.05 for all). Results did not differ by EF (P=0.60 interaction term of TNFα and EF). Conclusions - TNFα was elevated in a large portion of community HF patients, was associated with a large decrease in survival, and provided a significant incremental increase in risk assessment above established indicators. TNFα is useful for risk assessment in HF patients with preserved and reduced EF.
KW - Epidemiology
KW - Heart failure
KW - Inflammation
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=50349097674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50349097674&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.107.759191
DO - 10.1161/CIRCULATIONAHA.107.759191
M3 - Article
C2 - 18645056
AN - SCOPUS:50349097674
SN - 0009-7322
VL - 118
SP - 625
EP - 631
JO - Circulation
JF - Circulation
IS - 6
ER -